Sarepta Therapeutics (SRPT)
(Real Time Quote from BATS)
$131.43 USD
-0.39 (-0.30%)
Updated May 13, 2024 03:00 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
SRPT 131.43 -0.39(-0.30%)
Will SRPT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SRPT
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
Other News for SRPT
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Nevro Corp (NVRO) and Apellis Pharmaceuticals (APLS)
HHS panel to vote in Nov. on DMD screening for newborns
Boy given Pfizer experimental Duchenne muscular dystrophy therapy dies
Young boy dies in trial of Pfizer DMD gene therapy, STAT reports
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire